Regulatory‐Driven Pharmacokinetic and Immunogenicity Study of Siltartoxatug, a Recombinant Native Human Monoclonal Antibody Against Tetanus Toxin, in Cynomolgus Monkeys

Xia Zhou, Fei Zhou, Zhenpeng Fu, Weijun Ye, Guo Li, Jason Li, Weihong Zheng, Hua-Xin Liao, Shaojie Wang, Xiaoyi Liu · 2026

Read Regulatory‐Driven Pharmacokinetic and Immunogenicity Study of Siltartoxatug, a Recombinant Native Human Monoclonal Antibody Against Tetanus Toxin, in Cynomolgus Monkeys by Xia Zhou, Fei Zhou, Zhenpeng Fu, Weijun Ye, Guo Li, Jason Li, Weihong Zheng, Hua-Xin Liao, Shaojie Wang, Xiaoyi Liu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13678113.txt.

Description

Xia Zhou and nine colleagues published a 2026 drug study of siltartoxatug, a manufactured antibody against tetanus toxin. Tetanus prevention after wounds has long relied on antibody preparations drawn from human or animal blood, with supply and safety limits. Siltartoxatug is a fully human monoclonal antibody made in the laboratory, approved in China in February 2025 for urgent tetanus prevention.

This preclinical study, run to regulatory standards, examined how the drug behaves in cynomolgus monkeys. The researchers tracked its pharmacokinetics, how the body absorbs, distributes, and clears it over time. They also measured immunogenicity, whether the monkeys' immune systems reacted against the drug. Such animal data underpins the safety case for human use.

Catalog record

CREATORXia Zhou, Fei Zhou, Zhenpeng Fu, Weijun Ye, Guo Li, Jason Li, Weihong Zheng, Hua-Xin Liao, Shaojie Wang, Xiaoyi Liu
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE35 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13678113

Browse the full library · About the Tower of Babel